Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$136.63 USD
-1.84 (-1.33%)
Updated Oct 10, 2025 04:00 PM ET
After-Market: $136.57 -0.06 (-0.04%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
NBIX 136.63 -1.84(-1.33%)
Will NBIX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for NBIX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NBIX
GRFS or NBIX: Which Is the Better Value Stock Right Now?
GRFS or NBIX: Which Is the Better Value Stock Right Now?
NBIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus
Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q2 Earnings
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates
Other News for NBIX
Is NBIX likely to continue higher? Directional Movement Crossover Bullish shows up after sliding 0.44%
Neurocrine price target raised to $195 from $188 at UBS
Neurocrine price target raised by $7 at UBS, here's why
Is NBIX poised for gains? Crossed Above 50 Day Moving Average shows up after rising 1.52%
UBS Analyst Raises Price Target for Neurocrine Biosciences (NBIX) | NBIX Stock News